Small compounds for targeted radiotherapy
Appears in the following Collection
- Kjemisk institutt 
AbstractList of papers
E. M. Brevik, E. Årstad, P. Hoff. An improved synthesis of an 125I- and 211At-labelled benzamide for melanoma imaging. Proceedings of the 14th Radiochemical Conference, Mariánské Lázně 14–19 April 2002, Czech Republic. Czech. J. Phys. 53 (2003), Suppl.A A725–A729 Czech. J. Phys. 53 (2003), Suppl.A A725–A729
E. M. Brevik, E. Årstad, P. Hoff. Synthesis and biodistribution of N-(2-diethylaminoethyl)-3-[211At]astato-4-methoxy-benzamide for targeted radiotherapy of malignant melanoma. Manuscript. To be submitted to Melanoma Research.
E. M. Brevik, E. Årstad, F. O. Levy, P. Hoff. Evaluation of 125I- and 211At -labelled benzamides for targeting of σ1-receptors in an amelanotic melanoma xenograft. Manuscript. To be submitted to Melanoma Research.
E. M. Brevik, K. H. Holm, D. S. Wilbur, D. K. Hamlin, P. Hoff. Syntheses and preliminary biodistribution studies of radioiodinated cysteaminylphenol derivatives for malignant melanoma. Manuscript. To be submitted to Nuclear Medicine and Biology.
E. M. Brevik, A. Skretting, S. Bruheim, T. Bach-Gansmo, E. Årstad, P. Hoff. Pharmacokinetic properties and bone surface uptake of 1-hydroxy-(m-[123I]iodophenyl)-ethylidene-1,1-bisphosphonic acid (123I-HIPEBA) in pigs: implications for targeted radiotherapy. Manuscript. To be submitted to Nuclear Medicine Communications.